Intra-Cellular Therapies Inc (ITCI)
131.45
0.00 (0.00%)
USD |
NASDAQ |
Mar 18, 16:00
131.47
+0.02
(+0.02%)
After-Hours: 20:00
Intra-Cellular Therapies Revenue (Quarterly): 199.22M for Dec. 31, 2024
View 4,000+ Financial Data Types:
Add
Browse
Revenue (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Revenue (Quarterly) Benchmarks
| Johnson & Johnson | 22.52B |
| Moderna Inc | 956.00M |
| Eli Lilly and Co | 13.53B |
| AbbVie Inc | 15.10B |
| Sage Therapeutics Inc | 12.82M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -16.88M |
| Total Expenses (Quarterly) | 228.42M |
| EPS Diluted (Quarterly) | -0.16 |
| Enterprise Value | 12.98B |
| Gross Profit Margin (Quarterly) | 89.76% |
| Profit Margin (Quarterly) | -8.48% |
| Earnings Yield | -0.56% |
| Normalized Earnings Yield | -0.5553 |